CompletedPhase 4

Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

Russia370 participantsStarted 2021-01-01

Plain-language summary

The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of renal function in acute decompensation of chronic heart failure (ADHF) compared to standard therapy will be analyzed. Based on the dynamics of the clinical condition, the duration of hospitalization, and blood biochemical parameters (creatinine, urea, uric acid, potassium, sodium, N-terminal pro-brain natriuretic peptide - NT-proBNP) conclusions will be drawn about the possibility of using SGLT2i in this group of patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Cardiogenic shock (systolic blood pressure \<90 mm Hg; signs of hypoperfusion (altered mental status, cold skin, diuresis \<30 ml / hour, blood lactate level \>2.0 mmol / l).
✕. Urinary tract infection
✕. Type 1 diabetes mellitus (DM1), episodes of diabetic ketoacidosis or hypoglycemia
✕. Prior use of drugs from the SGLT2i group, taken regularly within 4 weeks
✕. GFR\<30 ml / min / 1.73 m2 (CKD-EPI).
✕. Individual SGLT2i intolerance
✕. Child-Pugh class C liver failure
✕. Mental illness (inability to sign an informed consent, lack of understanding of possible consequences)

What they're measuring

death due to heart failure

Timeframe: through study completion, an average of 5 days

Trial details

NCT IDNCT04778787

SponsorI.M. Sechenov First Moscow State Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-01

View on ClinicalTrials.gov More Congestive Heart Failure trials